-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

Benzinga·09/22/2026 10:09:16
Listen to the news
BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $34.